Phase 4Completed

Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD (IDEAL)

Atorvastatin Compared With Simvastatin In The Prevention of CHD Morbidity And Mortality In Patients With CHD

Sponsor
Pfizer (Industry)
Enrollment
8,600 planned
Conditions
Cardiovascular Diseases
Interventions
atorvastatin; simvastatin
Ages
children, adults, older adults
Registry
NCT00159835

Full record on ClinicalTrials.gov

From the registry

To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.

Primary outcomes

  • Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest

History

  1. Last registry update

  2. Registered

  3. Study completion

  4. Started